Table of contents
Expand All Topics
Vulvovaginal atrophy
Guidelines
Key sources
The following summarized guidelines for the evaluation and management of vulvovaginal atrophy are prepared by our editorial team based on guidelines from the Society of Obstetricians and Gynaecologists of Canada (SOGC 2021,2014), the Endocrine Society (ES 2015), the American College of Obstetricians and Gynecologists (ACOG 2014), the North American Menopause Society (NAMS 2013), and the American Association of Clinical Endocrinologists ...
Show more
Screening and diagnosis
Diagnostic investigations
Evaluation of vaginal bleeding: as per ES 2015 guidelines, obtain evaluation to rule out pelvic pathology, most importantly endometrial hyperplasia and cancer, in patients with persistent unscheduled bleeding while taking menopausal hormone therapy.
B
More topics in this section
Evaluation of sexual dysfunction
Medical management
Vaginal lubricants and moisturizers: as per SOGC 2021 guidelines, consider offering vaginal lubricants and moisturizers for the treatment of vaginal atrophy related to menopause.
B
More topics in this section
Local estrogen therapy
Systemic estrogen therapy
Therapeutic procedures
Specific circumstances
Patients with breast cancer
As per SOGC 2014 guidelines:
Discuss quality-of-life considerations when considering the use of intravaginal estrogen therapy for severe vulvovaginal atrophy in patients with breast cancer, as well as the uncertainty regarding effects on breast cancer recurrence.
B
Discuss the uncertainty of risks associated with systemic hormone therapy after a diagnosis of breast cancer in patients seeking treatment for distressing symptoms (vasomotor symptoms or vulvovaginal atrophy).
B
More topics in this section
Patients with endometrial cancer
Patients with hormone-independent cancer